Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations
-
- Shibata Masaaki
- Department of Pharmacy, National Hospital Organization Nagoya Medical Center
-
- Takahashi Masaaki
- Department of Pharmacy, National Hospital Organization Nagoya Medical Center
-
- Yoshino Munehiro
- Department of Pharmacy, National Hospital Organization Osaka Medical Center
-
- Kuwahara Takeshi
- Department of Pharmacy, National Cerebral and Cardiovascular Center Hospital
-
- Nomura Toshiharu
- Department of Pharmacy, National Hospital Organization Nagoya Medical Center
-
- Yokomaku Yoshiyuki
- Department of Clinical Research Center, National Hospital Organization Nagoya Medical Center
-
- Sugiura Wataru
- Department of Clinical Research Center, National Hospital Organization Nagoya Medical Center
Search this article
Abstract
Rilpivirine (TMC-278) is a second-generation non-nucleoside reverse transcriptase inhibitor that is high potent against both wild-type and drug-resistant HIV-1 strains. Therefore, rilpivirine is expected to treat therapy-experienced patients who failed to use current drugs due to the emergence of drug-resistant HIV mutants. The quantification of rilpivirine in human plasma is important to support clinical studies and determine pharmacokinetic parameters of rilpivirine in HIV-1 infected patients. Consequently, simple and easy system to determine plasma rilpivirine concentrations has been required. In this study, we developed a conventional LC-MS method to quantify plasma rilpivirine. Subsequently the method was validated by estimating the precision and accuracy for inter- and intraday analysis in the concentration range of 18-715 ng/ml. The calibration curve was linear in this range. Average accuracy ranged from 100.0 to 100.6%. Relative standard deviations of both inter- and intraday assays were less than 3.3%. Recovery of rilpivirine was more than 82.0%. These results demonstrate that our LC-MS method provides a conventional, accurate and precise way to determine rilpivirine in human plasma. This method can be used in routine clinical application for HIV-1 infected patients, and permits management of drug interactions and toxicity for rilpivirine. J. Med. Invest. 60: 35-40, February, 2013
Journal
-
- The Journal of Medical Investigation
-
The Journal of Medical Investigation 60 (1.2), 35-40, 2013
The University of Tokushima Faculty of Medicine
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204245101696
-
- NII Article ID
- 120005380899
- 130004465291
-
- NII Book ID
- AA11166929
-
- ISSN
- 13496867
- 13431420
-
- PubMed
- 23614909
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- IRDB
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed